OFIXOrthofix Medical Inc.

Orthofix Medical recently saw its analyst price target move from US$15 to US$13, a reset that anchors the latest round of valuation work on the stock. Analysts link this change to updated views on revenue, cash generation and the impact of the MDR transition, even as many maintain a constructive long-term stance. Read on to see what is driving the shift in targets and how you can track the evolving Orthofix Medical story from here. Analyst Price Targets don't always capture the full story...

Orthofix Medical (NASDAQ:OFIX) executives said the company’s updated outlook reflects the restoration of bone growth stimulation reimbursement, improving trends in biologics and limb reconstruction, and an expected European inventory order, partly offset by a steeper-than-anticipated decline among s

Biologics stabilize while spine fixation grows double-digit internationally.

Orthofix Medical Inc (OFIX) delivers 5% pro forma growth, raises EBITDA guidance, and navigates a complex landscape of European MDR opportunities and U.S. distributor headwinds.

Orthofix Medical (NASDAQ:OFIX) reported second-quarter results that management said reflected improving operating trends across several businesses, while continued weakness among smaller U.S. spine distributors remained a headwind. The company reiterated its focus on commercial productivity, discipl

Moby summary of Orthofix Medical Inc.'s Q2 2026 earnings call

Orthofix (OFIX) delivered earnings and revenue surprises of +333.33% and +0.67%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Orthofix (OFIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Rewey Asset Management, an investment management firm, released its “RAM Smid Composite” investor letter for the second quarter of 2026. A copy of the letter can be downloaded here. Rewey Asset Management, an investment management firm, released its “RAM Smid Composite” investor letter for the second quarter of 2026. RAM Smid Composite gained 20.06% in the […]

The average of price targets set by Wall Street analysts indicates a potential upside of 33.3% in Orthofix (OFIX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.